生物标志物诊断工具在新冠肺炎患者中的作用：分层变得简单。
Role of Biomarkers Diagnostic Tools in Patients with COVID-19: Stratification Made Easy.
作者信息
Salman Ahmed Abdallah, Abdallah Heba Mohamed, Eldahdouh Sami, Elkhadry Sally Waheed, Awad Samah Mohamed, Gaballah Ghada M K, Awaad Eman Kamal, Saad Mohammed Gaber, Taha Ahmed E, Gaballa Nahla K
机构信息
Internal Medicine Department, Faculty of medicine, Cairo University, Cairo, Egypt.
Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin Elkom, Egypt.
出版信息
Int J Gen Med. 2024 Oct 25;17:4895-4906. doi: 10.2147/IJGM.S488968. eCollection 2024.
BACKGROUND AND AIMS
In coronavirus disease 2019 (COVID-19) patients, several serum biomarkers have been identified. Upon intensive care unit (ICU) admission, these laboratory markers become more crucial to distinguish between patients with severe cases of COVID-19. It might assist doctors in predicting the course of illnesses and treating patients appropriately. This work was to investigate the role of biomarkers in patients with COVID-19 classification admitted to the hospital and identified by reverse transcription polymerase chain reaction (RT-PCR).
METHODS
Peripheral blood sample was taken from COVID-19 cases isolated on admission to determine C-reactive protein (CRP), D-dimer, Fibrinogen, neutrophil-lymphocyte ratio (NLR), leukocytes CRP ratio (LeCR), lymphocyte-CRP ratio (LCR), interleukin-6 (IL6), leukocytes interleukin 6 ratio (LeIL6), systemic inflammatory index (SII), platelet-to-lymphocyte ratio (PLR), and tissue plasminogen activator inhibitor one (tPAI-1). Follow-up for IL6, Ferritin, D-dimer, and tPAI-1 were determined on the 3 and 7 days.
RESULTS
Comparisons of severity revealed that hypertension, chronic obstructive pulmonary disease (COPD), and Ischemia were major risk factors in COVID-19 patients. There was a statistically significant difference between the test groups for fibrinogen (p < 0.000), IL6 (p < 0.009), LeCR (p < 0.006), and LCR (p < 0.011).
CONCLUSION
Based on laboratory test findings at the time of ICU admission, we can distinguish severe cases of COVID-19.
背景与目的
在2019冠状病毒病（COVID-19）患者中，已鉴定出多种血清生物标志物。在重症监护病房（ICU）入院时，这些实验室指标对于区分COVID-19重症患者变得更为关键。它可能有助于医生预测疾病进程并适当治疗患者。本研究旨在调查通过逆转录聚合酶链反应（RT-PCR）确诊并入院的COVID-19患者中生物标志物的作用。
方法
采集入院时隔离的COVID-19病例的外周血样本，以测定C反应蛋白（CRP）、D-二聚体、纤维蛋白原、中性粒细胞与淋巴细胞比值（NLR）、白细胞与CRP比值（LeCR）、淋巴细胞与CRP比值（LCR）、白细胞介素6（IL6）、白细胞与白细胞介素6比值（LeIL6）、全身炎症指数（SII）、血小板与淋巴细胞比值（PLR）以及组织纤溶酶原激活物抑制剂1（tPAI-1）。在第3天和第7天测定IL6、铁蛋白、D-二聚体和tPAI-1的随访指标。
结果
严重程度比较显示，高血压、慢性阻塞性肺疾病（COPD）和缺血是COVID-19患者的主要危险因素。试验组之间纤维蛋白原（p < 0.000）、IL6（p < 0.009）、LeCR（p < 0.006）和LCR（p < 0.011）存在统计学显著差异。
结论
根据ICU入院时的实验室检查结果，我们可以区分COVID-19重症病例。
Zotero 插件